Immune suppression in the tumor microenvironment: A role for dendritic cell-mediated tolerization of T cells

Cancer Immunology, Immunotherapy

Volumn 61, Issue 2, 2012, Pages 289-293

  Hurwitz, Arthur A ^a   Watkins, Stephanie K ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

CITIM 2011; Suppression; T cell; Tolerance; Tumor microenvironment

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR FKHRL1; TUMOR ANTIGEN;

ADAPTIVE IMMUNITY; ANTIGEN EXPRESSION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CROSS PRESENTATION; DENDRITIC CELL; GENE EXPRESSION REGULATION; HUMAN; IMMUNE DEFICIENCY; IMMUNOLOGICAL TOLERANCE; MALIGNANT TRANSFORMATION; METASTASIS; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; T LYMPHOCYTE; TOLEROGENIC DENDRITIC CELL; TUMOR ESCAPE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGENS, NEOPLASM; DENDRITIC CELLS; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84856731500     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1181-5     Document Type: Review

References (30)

1. AJ Adler DW Marsh GS Yochum JL Guzzo A Nigam WG Nelson DM Pardoll 1998 CD4+ T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells J Exp Med 187 1555 1564 9584134 10.1084/jem.187.10.1555 1:CAS:528:DyaK1cXjtFaisLg%3D (Pubitemid 28235097)
2. N Cools P Ponsaerts TV Van ZN Berneman 2007 Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells J Leukoc Biol 82 1365 1374 17711977 10.1189/jlb.0307166 1:CAS:528:DC%2BD2sXhsValtbfM (Pubitemid 350276946)
3. Y Ben-Neriah M Karin 2011 Inflammation meets cancer, with NF-kappaB as the matchmaker Nat Immunol 12 715 723 21772280 10.1038/ni.2060 1:CAS:528:DC%2BC3MXptV2isrk%3D
4. D Hanahan RA Weinberg 2011 Hallmarks of cancer: the next generation Cell 144 646 674 21376230 10.1016/j.cell.2011.02.013 1:CAS:528:DC%2BC3MXjsFeqtrk%3D
5. ML Belladonna C Volpi R Bianchi, et al. 2008 Cutting edge: autocrine TGF-beta sustains default tolerogenesis by IDO-competent dendritic cells J Immunol 181 5194 5198 18832670 1:CAS:528:DC%2BD1cXhtF2hs7jJ
6. N Cools TV Van EL Smits M Lenjou G Nijs DR Van Bockstaele ZN Berneman P Ponsaerts 2008 Immunosuppression induced by immature dendritic cells is mediated by TGF-beta/IL-10 double-positive CD4+ regulatory T cells J Cell Mol Med 12 690 700 18419605 10.1111/j.1582-4934.2007.00084.x 1:CAS:528:DC%2BD1cXms1aqu7o%3D (Pubitemid 351555146)
7. JB Katz AJ Muller GC Prendergast 2008 Indoleamine 2, 3-dioxygenase in T-cell tolerance and tumoral immune escape Immunol Rev 222 206 221 18364004 10.1111/j.1600-065X.2008.00610.x 1:CAS:528:DC%2BD1cXlsFejt70%3D (Pubitemid 351430372)
8. R Ganss D Hanahan 1998 Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes Cancer Res 58 4673 4681 9788621 1:CAS:528:DyaK1cXmslWrsbw%3D (Pubitemid 28480634)
9. MJ Anderson K Shafer-Weaver NM Greenberg AA Hurwitz 2007 Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer J Immunol 178 1268 1276 17237372 1:CAS:528: DC%2BD2sXntVGisg%3D%3D (Pubitemid 46154596)
10. Hurwitz AA, Foster BA, Allison JP, Greenberg NM, Kwon ED (2001) The TRAMP mouse as a model for prostate cancer. Curr.Protoc.Immunol (Chapter 20)
11. KA Shafer-Weaver MJ Anderson K Stagliano A Malyguine NM Greenberg AA Hurwitz 2009 Cutting edge: tumor-specific CD8+ T cells infiltrating prostatic tumors are induced to become suppressor cells J Immunol 183 4848 4852 19801511 10.4049/jimmunol.0900848 1:CAS:528:DC%2BD1MXht1WhsLjN
12. KA Shafer-Weaver SK Watkins MJ Anderson LJ Draper A Malyguine WG Alvord NM Greenberg AA Hurwitz 2009 Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells Cancer Res 69 6256 6264 19622771 10.1158/0008-5472.CAN-08-4516 1:CAS:528:DC%2BD1MXpt1Cgur8%3D
13. SK Watkins Z Zhu E Riboldi KA Shafer-Weaver KE Stagliano MM Sklavos S Ambs H Yagita AA Hurwitz 2011 FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer J Clin Invest 121 1361 1372 21436588 10.1172/JCI44325
14. F Fallarino R Bianchi C Orabona C Vacca ML Belladonna MC Fioretti DV Serreze U Grohmann P Puccetti 2004 CTLA-4-Ig activates forkhead transcription factors and protects dendritic cells from oxidative stress in nonobese diabetic mice J Exp Med 200 1051 1062 15492127 10.1084/jem.20040942 1:CAS:528: DC%2BD2cXovVensb8%3D (Pubitemid 39431129)
15. L Lin JD Hron SL Peng 2004 Regulation of NF-kappaB, Th activation, and autoinflammation by the forkhead transcription factor Foxo3a Immunity 21 203 213 15308101 10.1016/j.immuni.2004.06.016 1:CAS:528:DC%2BD2cXnsVKlt7o%3D (Pubitemid 39094050)
16. I Fricke DI Gabrilovich 2006 Dendritic cells and tumor microenvironment: a dangerous liaison Immunol Invest 35 459 483 16916762 10.1080/08820130600803429 1:CAS:528:DC%2BD28XpvVCks7g%3D (Pubitemid 44266783)
17. CE Lewis JW Pollard 2006 Distinct role of macrophages in different tumor microenvironments Cancer Res 66 605 612 16423985 10.1158/0008-5472.CAN-05-4005 1:CAS:528:DC%2BD28XlsFOmtw%3D%3D (Pubitemid 43165918)
18. M Aalamian G Pirtskhalaishvili A Nunez C Esche GV Shurin E Huland H Huland MR Shurin 2001 Human prostate cancer regulates generation and maturation of monocyte-derived dendritic cells Prostate 46 68 75 11170134 10.1002/1097-0045(200101)46:1<68::AID-PROS1010>3.0.CO;2-2 1:STN:280:DC%2BD3M7ls1ShsQ%3D%3D (Pubitemid 32157778)
19. AS Dejean DR Beisner IL Ch'en YM Kerdiles A Babour KC Arden DH Castrillon RA DePinho SM Hedrick 2009 Transcription factor Foxo3 controls the magnitude of T cell immune responses by modulating the function of dendritic cells Nat Immunol 10 504 513 19363483 10.1038/ni.1729 1:CAS:528:DC%2BD1MXksVelur0%3D
20. A Kuraishy M Karin SI Grivennikov 2011 Tumor promotion via injury- and death-induced inflammation Immunity 35 467 477 22035839 10.1016/j.immuni.2011. 09.006 1:CAS:528:DC%2BC3MXhtlyjs7%2FL
21. WE Naugler T Sakurai S Kim S Maeda K Kim AM Elsharkawy M Karin 2007 Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production Science 317 121 124 17615358 10.1126/science.1140485 1:CAS:528:DC%2BD2sXnt1SjtLc%3D (Pubitemid 47056470)
22. S Kurinna SA Stratton WW Tsai KC Akdemir W Gu P Singh T Goode GJ Darlington MC Barton 2010 Direct activation of forkhead box O3 by tumor suppressors p53 and p73 is disrupted during liver regeneration in mice Hepatology 52 1023 1032 20564353 10.1002/hep.23746 1:CAS:528:DC%2BC3cXhtFyitrzO
23. K Khazaie NR Blatner MW Khan, et al. 2011 The significant role of mast cells in cancer Cancer Metastasis Rev 30 45 60 21287360 10.1007/s10555-011-9286- z 1:CAS:528:DC%2BC3MXitlKltLk%3D
24. P Pittoni C Tripodo S Piconese G Mauri M Parenza A Rigoni S Sangaletti MP Colombo 2011 Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers Cancer Res 71 5987 5997 21896641 10.1158/0008-5472.CAN-11-1637 1:CAS:528: DC%2BC3MXhtFKntb3M
25. Yang Z, Zhang B, Li D, Lv M, Huang C, Shen GX, Huang B (2010) Mast cells mobilize myeloid-derived suppressor cells and Treg cells in tumor microenvironment via IL-17 pathway in murine hepatocarcinoma model. PLoS One 5:e8922.2
26. VC de Vries RJ Noelle 2010 Mast cell mediators in tolerance Curr Opin Immunol 22 643 648 20884193 10.1016/j.coi.2010.08.015
27. SJ Galli M Grimbaldeston M Tsai 2008 Immunomodulatory mast cells: negative, as well as positive, regulators of immunity Nat Rev Immunol 8 478 486 18483499 10.1038/nri2327 1:CAS:528:DC%2BD1cXmt1Ojt78%3D (Pubitemid 351733419)
28. KN Rao MA Brown 2008 Mast cells: multifaceted immune cells with diverse roles in health and disease Ann N Y Acad Sci 1143 83 104 19076346 10.1196/annals.1443.023 1:CAS:528:DC%2BD1MXpvFKrug%3D%3D
29. Watkins SK, Zhu Z, Riboldi E, Shafer-Weaver KA, Stagliano KER, Sklavos MM, Ambs S, Yagita H, Hurwitz AA (2011) Foxo3a programs tumor associated dendritic cells to become tolerogenic in human and murine prostate cancer. J Clin Investig 121
30. EJ Small PF Schellhammer CS Higano CH Redfern JJ Nemunaitis FH Valone SS Verjee LA Jones RM Hershberg 2006 Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer J Clin Oncol 24 3089 3094 16809734 10.1200/JCO.2005.04.5252 1:CAS:528:DC%2BD28XnslKhs7g%3D (Pubitemid 46638945)